Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: A clinical cohort study with natural history comparator

The Lancet Neurology

Volumn 14, Issue 5, 2015, Pages 497-505

  Palace, Jacqueline ^a   Duddy, Martin ^b   Bregenzer, Thomas ^c   Lawton, Michael ^d   Zhu, Feng ^e   Boggild, Mike ^f   Piske, Benjamin ^c   Robertson, Neil P ^g   Oger, Joel ^e   Tremlett, Helen ^e   Tilling, Kate ^d   Ben Shlomo, Yoav ^d   Dobson, Charles ^h  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c PAREXEL INTERNATIONAL   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f TOWNSVILLE HOSPITAL   (Australia)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h Department of Health ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOLOGIC FACTOR; PEPTIDE;

ADULT; ARTICLE; CANADA; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG EFFICACY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HISTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; FOLLOW UP; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK; YOUNG ADULT;

ADULT; BRITISH COLUMBIA; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; RISK; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928046797     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00018-6     Document Type: Article

References (34)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655-661. The IFNB Multiple Sclerosis Study Group.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
3. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498-1504. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group.
4. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
5. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998, 352:1491-1497. European Study Group on interferon β-1b in secondary progressive MS.
6. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001, 56:1496-1504. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group.
7. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004, 63:1788-1795. North American Study Group on Interferon β-1b in Secondary Progressive MS.
8. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003, 361:545-552.
9. Clegg A, Bryant J Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness. Expert Opin Pharmacother 2001, 2:623-639.
10. La Mantia L, Munari LM, Lovati R Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010, 5. CD004678.
11. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE technology appraisal guidance no. 32 2002, National Institute for Clinical Excellence, National Institute for Clinical Excellence, London.
12. Cost effective provision of disease modifying therapies for people with multiple sclerosis. Health Service Circular (2002/004) 2002, Department of Health, Stationery Office, London.
13. Chilcott J, McCabe C, Tappenden P, Cooper NJ, Abrams K, Claxton K Modelling the cost-effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003, 326:522-526.
14. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009, 339:b4677.
15. Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014, 4:e004073.
16. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
17. Tremlett H, Paty D, Devonshire V Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006, 66:172-177.
18. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M New perspectives in the natural history of multiple sclerosis. Neurology 2010, 74:2004-2015.
19. Orme M, Kerrigan J, Tyas D, Russell N, Nixon R The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007, 10:54-60.
20. Jackson CH, Sharples LS, Thompson SG, et al. Multistate Markov models for disease progression with classification error. J R Stat Soc 2003, 52:193-209.
21. Harding KE, Wardle M, Moore P, et al. Modelling the natural history of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2015, 86:13-19.
22. Little RJA, Rubin DB Statistical analysis with missing data 1987, J Wiley & Sons, New York, NY.
23. Noyes K, Bajorska A, Chappel A, et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011, 77:355-363.
24. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?. Neurology 2007, 69:1498-1507.
25. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010, 81:907-912. for the Investigators of the 16-Year Long-Term Follow-up Study.
26. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007, 61:300-306.
27. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012, 308:247-256.
28. Karim ME, Gustafson P, Petkau J, et al. Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol 2014, 180:160-171.
29. Renoux C, Suissa S Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol 2008, 64:109-110.
30. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler 2013, 19:577-584. for the UBC MS Clinic Neurologists.
31. Inusah S, Sormani MP, Cofield SS Assessing changes in relapse rates in multiple sclerosis. Mult Scler 2010, 16:1414-1421.
32. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler 2012, 18:442-450.
33. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009, 67:99-109.
34. Hodgson R, Bushe C, Hunter R Measurement of long-term outcomes in observational and randomised controlled trials. Br J Psychiatry 2007, 50(suppl):s78-s84.